HeartFlow Logo

Enabling Better Care
Decisions in the UK

Transforming the Way Coronary Artery Disease
is Diagnosed and Treated


The HeartFlow FFRCT Analysis is the first non-invasive diagnostic tool that aids clinicians in determining, vessel by vessel, both the extent of an artery’s narrowing and the impact that the narrowing has on blood flow to the heart.

By non-invasively identifying which patients do and do not need intervention, clinicians can reduce unnecessary invasive testing, reduce healthcare system costs and improve patient quality of life.

A dark grey anatomical heart graphic with coloured vessels around it with a play button overlay indicating a link to click to watch a video

Improving the Health of Populations

Enhancing the Patient Experience

Reducing Costs

NICE Guidance

The National Institute for Health and Care Excellence (NICE) provides national guidance and quality standards to improve health and social care within the UK’s National Health Service (NHS).

NICE issued a Technology Assessment (MTG32) in February 2017 endorsing the use of the HeartFlow® FFRCT Analysis to help physicians determine the cause of stable chest pain in patients. This guidance follows the Chest Pain Guidelines (CG95) issued in November 2016, recommending non-invasive coronary CT angiography (CTCA) as the initial diagnostic test for patients with stable chest pain.

In April 2021, NICE released an updated review of MTG32 which found the following:

  • Based on the clinical evidence, NICE continues to endorse use of the HeartFlow FFRCT Analysis
  • The HeartFlow FFRCT Analysis is safe, and has a high level of diagnostic accuracy
  • Improves the specificity of CTCA and reduces “false positives by as much as 50%” and reduces the need for diagnostic angiography
  • Provides cost saving of £391 per patient to NHS (£177 higher than 2017 assessment) relative to other noninvasive testing modalities
  • Funding for HeartFlow has transitioned to the new MedTech Funding Mandate.
    “All NHSE providers and NHSE Commissioners are expected to comply with the Mandate guidance and CCG’s are expected to fund HeartFlow from 1st April 2021.”
  • More than 15,000 NHS patients have received the HeartFlow FFRCT Analysis

IMPORTANT NOTICE: As part of the MedTech Funding Mandate starting on 1 April 2021, the HeartFlow FFRCT Analysis is available to order via the NHS Supply Chain catalogue and managed by the Medical IT Departmental Software and Hardware Solutions Framework, within NHS Supply Chain: Large Diagnostic Capital Equipment including Mobile and Services. More information on this can be found through the NHS Supply Chain website or you can download the Order Guide here.

NICE Resources

NICE MTG32 Guidance Overview
Patient Education Brochure
NICE Updated Guidance (April 2021)
NICE Guidance: Patient Diagnosis Workflow
NICE CG95 Guidance
More Resources at nice.org.uk

UK News

Press Release: NICE renews support for use of AI-powered HeartFlow Analysis in heart disease diagnosis
Press Release: NHS England and NHS Improvement mandate adoption of AI-powered HeartFlow Analysis to fight coronary heart disease
Press Release: NICE Guidance Recommends HeartFlow FFRCT Analysis to Help Determine Cause of Stable Chest Pain in Patients
Case Study: Portsmouth Hospitals University NHS Trust (Queen Alexandra Hospital)
Case Study: Manchester University NHS Foundation Trust
Case Study: Royal Stoke University Hospital
Case Study: Royal Cornwall Hospitals

HeartFlow Finder

0 results for out of Printer icon

Don't see a listing in your area? Submit a request, and we'll try to bring the HeartFlow Analysis closer to you.

Contact Us


* Required fields

REFERENCES

  1. Douglas, et al. Eur Heart J. 2015.
  2. Douglas, et al. J Am Coll Cardiol. 2016.
  3. Hlatky, et al. J Am Coll Cardiol. 2015.
  4. National Institute for Health and Care Excellence (2017). HeartFlow FFRCT for estimating fractional flow reserve from coronary CT angiography. NICE medical technology guidance, February 2017. London: NICE.

15991305 v2